Clinical Trial

Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients With Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure

Study acronym: CONTROL-ACLF
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Phase 2 Study of 500 mg BID NTZ on Top of Standard of Care in Patients with Acute Decompensation of Liver Cirrhosis at High Risk of Progression to Acute-on-Chronic Liver Failure or Established Acute-on-Chronic Liver Failure
Trial Details
NCT Number NCT07694297
Lead Sponsor Genfit
Conditions Acute Decompensation of Liver Cirrhosis, Established Acute-on-Chronic Liver Failure
Enrollment 16 participants
Start Date 2026-10
Primary Completion 2027-08 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-09